Calcium and cardiovascular risk: What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?

BMJ (Online)

Volumn 346, Issue 7910, 2013, Pages

  Bolland, Mark J ^a   Avenell, Alison ^b   Grey, Andrew ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; STRONTIUM RANELATE; VITAMIN D;

CALCIUM INTAKE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DRUG SAFETY; FRACTURE; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; LETTER; MORTALITY; OSTEOPOROSIS; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

EID: 84878599127     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f3413     Document Type: Letter

References (5)

1. Medicines and Healthcare Products Regulatory Agency. Strontium ranelate (Protelos): risk of serious cardiac disorders-restricted indications, new contraindications, and warnings. Drug Safety Update 2013;6:S1.
2. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006;3:CD005326.
3. Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008;19:1119-23.
4. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040.
5. Medicines and Healthcare Products Regulatory Agency. Calcium and vitamin D: studies of cardiovascular risk do not support prescribing changes. Drug Safety Update A2011;5:H1.